Early effect of lipid-lowering therapy with pitavastatin on regression of coronary atherosclerotic plaque - Comparison with atorvastatin

Circulation Journal

Volumn 73, Issue 8, 2009, Pages 1466-1472

  Toi, Toru ^a   Taguchi, Isao ^a   Yoneda, Shuichi ^a   Kageyama, Michiya ^a   Kikuchi, Akiko ^a   Tokura, Michiaki ^a   Kanaya, Tomoaki ^a   Abe, Shichiro ^a   Matsuda, Ryuko ^a   Kaneko, Noboru ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Atherosclerosis; Intravascular ultrasound; Pitavastatin; Virtual histology

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PITAVASTATIN; TRIACYLGLYCEROL;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; ATHEROSCLEROTIC PLAQUE; CATHETER; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY ATHEROSCLEROSIS; CORRELATION ANALYSIS; DIABETES MELLITUS; DISEASE COURSE; DRUG EFFECT; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMAGE ANALYSIS; INTRAVASCULAR ULTRASOUND; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDY; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; ULTRASOUND;

AGED; ANTILIPEMIC AGENTS; CHOLESTEROL; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; MALE; MIDDLE AGED; QUINOLINES; TIME FACTORS;

EID: 69049092983     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-08-1051     Document Type: Article

References (31)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
2. Sacks FM, Peffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009.
3. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-1357.
4. Pitt B, Waters D, Brown WV, van Boven AJ, Schwartz L, Title LM, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 1999; 341: 70-76.
5. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. JAMA 2001; 285: 1711-1718.
6. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: A randomized placebo-controlled trial. Lancet 2002; 360: 7-22.
7. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruncher JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425-1435.
8. Cannon CP, Braunworld E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-1504.
9. Grundy SM, Cleeman JI, Merz NB, Brewer HB, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation 2004; 110: 227-239.
10. Teramoto T, Sasaki J, Ueshima H, Egusa G, Kinoshita M, Shimamoto K, et al. Executive Summary of Japan Atherosclerosis Society (JAS) Guideline for Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases for Japanese. J Atheroscler Thromb 2007; 14: 45-50.
11. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, et al. Effect of intensive compared with moderate lipid-lowering therapy progression of coronary atherosclerosis. JAMA 2004; 291: 1071-1080.
12. Okazaki S, Yokoyama T, Miyauchi K, Shimada K, Kurata T, Sato H, et al. Early statin treatment in patients with acute coronary syndrome: Demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: The ESTABLISH Study. Circulation 2004; 110: 1061-1068.
13. Miyauchi K, Kimura T, Morimoto T, Nakagawa Y, Yamagishi M, Ozaki Y, et al. Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS): Rationale and design. Circ J 2006; 70: 1624-1628.
14. Takashima H, Ozaki Y, Yasukawa T, Waseda K, Asai K, Wakita Y, et al. Impact of lipid-lowering therapy with pitavastatin, a new HMG-CoA reductase inhibitor, on regression of coronary atherosclerotic plaque: A 3-dimensional intravascular ultrasound study. Circ J 2007; 71: 1678-1684.
15. Yamada T, Azuma A, Sasaki S, Sawada T, Matsubara H. Randomized evaluation of atorvastatin in patients with coronary heart disease: A serial intravascular ultrasound study. Circ J 2007; 71: 1845-1850.
16. Schartl M, Bocksch W, Koschyk DH, Voelker W, Karsch KP, Kreuzer J, et al. Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation 2001; 104: 387-392.
17. Rodriguez-Granillo GA, Bruining N, McFadden E, Ligthart JM, Aoki J, Regar E, et al. Geometrical validation of intravascular ultrasound radiofrequency data analysis (Virtual Histology) acquired with a 30MHz Boston Scientific Corporation imaging catheter. Catheter Cardiovascular Interv 2005; 66: 504-508.
18. Murashige A, Hiro T, Fujii T, Imoto K, Murata T, Fukumoto Y, et al. Detection of lipid-laden atherosclerotic plaque by wavelet analysis of radiofrequency intravascular ultrasound signals: In vitro validation and preliminary in vivo application. J Am Coll Cardiol 2005; 45: 1954-1960.
19. Stähr PM, Höffinghous T, Voigtiänder T, Countney BK, Victor A, Otto M, et al. Discrimination of early/intermediate and advanced/complicated coronary plaque types by radiofrequency intravascular ultrasound analysis. Am J Cardiol 2002; 99: 19-23.
20. Komiyama N, Berry GJ, Kolz ML, Oshima A, Metz JA, Preuss P, et al. Tissue characterization of atherosclerotic plaques by intravascular ultrasound radiofrequency signal analysis: An in vitro study of human coronary arteries. Am Heart J 2000; 140: 565-574.
21. Nair A, Kuban BD, Tuzcu EM, Schoenhagen P, Nissen SE, Vince DG. Coronary plaque classification with intravascular ultrasound radiofrequency data analysis. Circulation 2002; 106: 2200-2206.
22. Nasu K, Tsuchikane E, Katoh O, Vince DG, Virmani R, Surmely JF, et al. Accuracy of in vivo coronary plaque morphology assessment: A validation study of in vivo virtual histology compared with in vitro histopathology. J Am Coll Cardiol 2006; 47: 2405-2412.
23. Ozaki Y, Violaris AG, Kobayashi T, Keane D, Camenzind E, Mario CD, et al. Comparison of coronary luminal quantification obtained from intracoronary ultrasound and both geometric and videodensitometoric quantitative angiography before and after balloon angioplasty and directional atherectomy. Circulation 1997; 96: 491-499.
24. Waseda K, Ozaki Y, Takashima H, Ako J, Yasukawa T, Ismail TF, et al. Impact of angiotensin II receptor blockers on the progression and regression of coronary atherosclerosis: An intravascular ultrasound study. Circ J 2006; 70: 1111-1115.
25. Nakamura T, Obata J, Kitta Y, Takano H, Kobayashi T, Fujioka D, et al. Rapid stabilization of vulnerable carotid plaque within 1 month of pitavastatin treatment in patients with acute coronary syndrome. J Cardiovasc Pharmacol 2008; 51: 365-371.
26. Kawakami A, Tani M, Chiba T, Yui K, Shinozaki S, Nakajima K, et al. Pitavastatin inhibits remnant lipoprotein-induced macrophage foam cell formation through ApoB48 receptor-dependent mechanism. Arterioscler Thromb Vasc Biol 2005; 25: 424-429.
27. Morishita R, Tomita N, Ogihara T. HMG-CoA reductase inhibitors in the treatment of cardiovascular diseases: Stabilization of coronary artery plaque. Curr Drug Targets 2002; 3: 379-385.
28. Fujino H, Kojima J, Yamada Y, Kanda H, Kimata H. Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (4): Interspecies variation in laboratory animals and humans. Xeno Metab Disp 1999; 14: 79-91.
29. Kohno M, Shinomiya K, Abe S, Noma T, Kondo I, Oshita A, et al. Inhibition of migration and proliferation of rat vascular smooth muscle cells by a new HMG-CoA reductase inhibitor, pitavastatin. Hypertens Res 2002; 25: 279-285.
30. Sakabe K, Fukuda N, Fukuda Y, Wakayama K, Nada T, Morishita S, et al. Comparisons of short- and intermediate-term effects of pitavastatin versus atorvastatin on lipid profiles, fibrinolytic parameter, and endothelial function. Int J Cardiol 2008; 125: 136-138.
31. Granada F, Wallace-Bradley D, Win H, Alviar C, Builes A, Lev E, et al. In vivo plaque characterization using intravascular ultrasound-virtual histology in a porcine model of complex coronary lesions. Arterioscler Thromb Vasc Biol 2007; 27: 387-393.